This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eiger BioPharmaceuticals Inc. netted $20mm through the follow-on public offering of 2.1mm common shares (including full exercise of the overallotment) at $10 each. The company will use some of the funds for ongoing development of its four candidates, all of which are in Phase II--ubenimex for lymphedema and hypertension (licensed from Nippon Kayaku), exendin 9-39 for hypoglycemia, pegylated interferon lambda for hepatitis delta virus (from BMS), and Sarasar (lonafarnib) for HDV (from Merck).
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?